research use only
Cat.No.S3243
| Related Targets | Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras KRas |
|---|---|
| Other Bcl-2 Inhibitors | Navitoclax (ABT-263) S63845 ABT-737 Obatoclax Mesylate (GX15-070) A-1331852 A-1210477 TW-37 A-1155463 Dihydrochloride AZD5991 UMI-77 |
|
In vitro |
CHCl3 : 4 mg/mL
DMSO
: Insoluble
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 568.87 | Formula | C40H56O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 144-68-3 | -- | Storage of Stock Solutions |
|
|
Read more about storage stability stock solution CAS number
| Targets/IC50/Ki |
Bcl-2
|
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2026-06-05)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05232409 | RECRUITING | Cancer Metastatic; Metastatic Solid Tumor |
Valley Health System |
2022-04-17 | PHASE1 |
| NCT06965426 | RECRUITING | Macular Degenerative Disease |
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, |
2025-06-01 | |
| NCT06489873 | RECRUITING | Cognitive Performance; Age-Related Macular Degeneration; Bone Loss |
Texas A&M University |
2024-02-07 | |
| NCT06237127 | Recruiting | Age-Related Macular Degeneration |
University of California Davis|United States Department of Agriculture (USDA) |
2024-04-29 | Not Applicable |
| NCT07355725 | COMPLETED | Cognitive |
Bioagile Therapeutics Pvt. Ltd. |
2022-07-21 | |
| NCT05283941 | Recruiting | Macular Degeneration|Retinal Degeneration|Retinal Diseases|Eye Diseases |
Tufts University|American Pistachio Growers |
2022-06-10 | Not Applicable |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.